These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32014105)

  • 1. [Non-mutated neoantigens, TEIPP, as new targets for cancer immunotherapies].
    Vouilloz A; Serre L
    Med Sci (Paris); 2020 Jan; 36(1):83-86. PubMed ID: 32014105
    [No Abstract]   [Full Text] [Related]  

  • 2. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I
    Marijt KA; Doorduijn EM; van Hall T
    Mol Immunol; 2019 Sep; 113():43-49. PubMed ID: 29627136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.
    Doorduijn EM; Sluijter M; Querido BJ; Oliveira CC; Achour A; Ossendorp F; van der Burg SH; van Hall T
    J Clin Invest; 2016 Feb; 126(2):784-94. PubMed ID: 26784543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.
    Khodadoust MS; Olsson N; Wagar LE; Haabeth OA; Chen B; Swaminathan K; Rawson K; Liu CL; Steiner D; Lund P; Rao S; Zhang L; Marceau C; Stehr H; Newman AM; Czerwinski DK; Carlton VE; Moorhead M; Faham M; Kohrt HE; Carette J; Green MR; Davis MM; Levy R; Elias JE; Alizadeh AA
    Nature; 2017 Mar; 543(7647):723-727. PubMed ID: 28329770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAP-ing into TIEPPs for cancer immunotherapy.
    Kiessling R
    J Clin Invest; 2016 Feb; 126(2):480-2. PubMed ID: 26784539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunology: protein surgery.
    Rammensee HG
    Nature; 2004 Jan; 427(6971):203-4. PubMed ID: 14724617
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer Neoantigens.
    Schumacher TN; Scheper W; Kvistborg P
    Annu Rev Immunol; 2019 Apr; 37():173-200. PubMed ID: 30550719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T Cell Epitope Prediction and Its Application to Immunotherapy.
    Schaap-Johansen AL; Vujović M; Borch A; Hadrup SR; Marcatili P
    Front Immunol; 2021; 12():712488. PubMed ID: 34603286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [TGF-β-targeted immunotherapy aiming for new and efficient treatments of cancer].
    Foughali R; Marie JC
    Med Sci (Paris); 2020 Jan; 36(1):77-79. PubMed ID: 32014103
    [No Abstract]   [Full Text] [Related]  

  • 10. Characterizing neoantigens for personalized cancer immunotherapy.
    Capietto AH; Jhunjhunwala S; Delamarre L
    Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy.
    Zhao W; Wu J; Chen S; Zhou Z
    Pharmacogenomics; 2020 Jun; 21(9):637-645. PubMed ID: 32423288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of HLA-A*0201/-A*2402-restricted CTL epitope-peptides derived from a novel cancer/testis antigen, MCAK, and induction of a specific antitumor immune response.
    Kawamoto M; Tanaka F; Mimori K; Inoue H; Kamohara Y; Mori M
    Oncol Rep; 2011 Feb; 25(2):469-76. PubMed ID: 21165574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New opportunities for the development of cancer immunotherapies.
    Rosenberg SA
    Cancer J Sci Am; 1998 May; 4 Suppl 1():S1-4. PubMed ID: 9619263
    [No Abstract]   [Full Text] [Related]  

  • 14. Modeling the specific CD4+ T cell response against a tumor neoantigen.
    Flament H; Alonso Ramirez R; Prémel V; Joncker NT; Jacquet A; Scholl S; Lantz O
    J Immunol; 2015 Apr; 194(7):3501-12. PubMed ID: 25732731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy.
    Ozaki Y; Kontani K; Teramoto K; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Asai T; Ohkubo I
    Biochem Biophys Res Commun; 2004 May; 317(4):1089-95. PubMed ID: 15094380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
    Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
    Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner.
    Kobayashi H; Nagato T; Sato K; Aoki N; Kimura S; Murakami M; Iizuka H; Azumi M; Kakizaki H; Tateno M; Celis E
    Cancer Res; 2007 Jun; 67(11):5498-504. PubMed ID: 17545632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Immunogenicity of a Proline-Substituted Altered Peptide Ligand toward the Cancer-Associated TEIPP Neoepitope Trh4 Is Unrelated to Complex Stability.
    Hafstrand I; Doorduijn EM; Sun R; Talyzina A; Sluijter M; Pellegrino S; Sandalova T; Duru AD; van Hall T; Achour A
    J Immunol; 2018 Apr; 200(8):2860-2868. PubMed ID: 29507106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II.
    SenGupta D; Norris PJ; Suscovich TJ; Hassan-Zahraee M; Moffett HF; Trocha A; Draenert R; Goulder PJ; Binder RJ; Levey DL; Walker BD; Srivastava PK; Brander C
    J Immunol; 2004 Aug; 173(3):1987-93. PubMed ID: 15265933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes.
    Ninkovic T; Hanisch FG
    J Immunol; 2007 Aug; 179(4):2380-8. PubMed ID: 17675499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.